Skip navigation

Navigate Regulatory Hurdles and Leverage Medical Utility, Safety and Efficacy Data to Advance Clinical Research

November 30-December 2, 2016
  • San Francisco, CA
Is your organization poised to unlock the potential medical utility of cannabis to treat a variety of conditions from Alzheimers and MS to PTSD, Hepatitis C and Oncology? Are you prepared to navigate the regulatory and drug development pathway to bring these novel treatments to patients?

CBI’s Cannabis-Based Therapies Summit navigates the rapidly evolving political and regulatory landscape around medical marijuana and cannabis-based research; offers insight into existing development hurdles including obtaining a DEA license and marijuana for IND/NDA approval, as well as the complexities of manufacturing through the drug development lifecycle. This groundbreaking summit is dedicated to advancing research and providing scientific data to support the medical utility of cannabis, uncovering safety and efficacy successes and challenges, tackling public opinion and fostering education for physicians, pharmacists and scientists. Hear sessions surrounding:

  • Up-to-the-minute coverage on the political and regulatory environment
  • In-depth analysis on current and future applications of cannabis research
  • Clinical drug development challenges, including obtaining a DEA Schedule I license, navigating NIDA and manufacturing requirements
  • Pharmaceuticals vs. nutraceuticals market trends and insight
  • Drug development approaches — NCE vs. biology/working with the plant
  • Benefits and shortfalls of observational research
  • Case studies of successes and drug development failures due to safety and efficacy
  • Educating the public, physicians and pharmacists on medical utility of cannabis

Leverage Cannabis Research Advancements as an Evolving Field in the Pharmaceutical Industry

  • Understand cannabis research successes and failures to date, both U.S. and globally
  • Evaluate new pharmaceutical products on the horizon and their advantages
  • Discuss clinical trial methodology and challenges for testing abuse and dependence potential as well as safety of cannabinoids
  • Analyze the regulatory pathways to obtain approval for use in various medical indications
  • Address hurdles when gaining approval from DEA and NIDA
  • Utilize cannabis as a non-opiate based treatment for PTSD, TBI, alcoholism, acute pain and trauma
  • Assess the phyto-cannabinoid pathway as the future of cannabinoid-based therapy development
  • Interpret and analyze observational data on medical cannabis patients to inform clinical research
  • Educate physicians and pharmacists on drug interactions with cannabis-based therapies
  • Review recent randomized double-blinded, placebo controlled trials of specific epilepsy syndromes

Nov 30 – DEC 1, 2016 Hyatt Centric San FranCisco, CA